Survodutide
BI 456906
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials for obesity and MASH; not yet approved by any regulatory authority.
Overview
Survodutide (BI 456906) is an investigational synthetic peptide developed by Boehringer Ingelheim that acts as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. Like mazdutide, survodutide is designed to combine incretin-mediated appetite suppression with glucagon-driven increases in energy expenditure and lipid metabolism.
Survodutide is administered as a once-weekly subcutaneous injection. It is currently being evaluated in multiple Phase 3 clinical trial programs and has not been approved by any regulatory authority for any indication as of early 2026.
Research context
Phase 2 data, published and presented at major medical conferences, evaluated survodutide at multiple dose levels in adults with overweight or obesity across 12 countries over 46 weeks. Results showed dose-dependent weight reductions, with higher doses demonstrating substantial effects. Survodutide has also been studied in the context of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), where Phase 2 data showed improvements in liver histology.
Phase 3 programs include the SYNCHRONIZE series (evaluating survodutide for obesity with or without type 2 diabetes and cardiovascular disease) and the ACHIEVE series (evaluating survodutide for MASH). These trials are enrolling participants across multiple countries and are expected to report results through 2026. The SYNCHRONIZE-2 trial specifically studies survodutide in adults with obesity and type 2 diabetes, with primary endpoints including body weight change and weight loss thresholds.
Safety and regulatory framing
Phase 3 SYNCHRONIZE program underway; also evaluated for MASH
Survodutide is an investigational drug that has not been approved by the FDA or any other regulatory authority. It is available only through enrollment in clinical trials. The Phase 2 safety profile was generally consistent with other incretin-class therapies, with gastrointestinal side effects being the most common.
As an investigational compound, survodutide is not legally available outside of clinical trials. Regulations vary by country. Readers should consult a licensed healthcare provider for decisions regarding investigational therapies or clinical trial enrollment.
References
- Busko M. "Survodutide Impresses in Phase 2 Weight-Loss Trial." Medscape (2023) ↗Medscape
- ClinicalTrials.gov: SYNCHRONIZE-2 (Survodutide Phase 3) ↗ClinicalTrials.gov
- Wharton S, et al. "Design of SYNCHRONIZE-2." Diabetes Obes Metab (2026) ↗Diabetes, Obesity and Metabolism
- Boehringer Ingelheim Survodutide Pipeline Page ↗Boehringer Ingelheim
Research information only
Peptide Daily is an informational resource only. Peptide research chemicals are not approved for human use by the FDA unless otherwise noted. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before using any peptide or research chemical.
New regulatory shifts matter as much as the peptide itself
Subscribe for editorial updates when major price moves, lab tests, or regulatory events affect the compounds you're tracking.
Weekly update
Get weekly peptide price intel
No spam, unsubscribe anytime.
Keep exploring the research context
Mazdutide
Mazdutide is a dual GLP-1/glucagon receptor agonist approved in China for weight management and T2D; currently in Phase 2 US trials. Not FDA-approved.
Retatrutide
Retatrutide is an investigational triple GLP-1/GIP/glucagon receptor agonist in Phase 3 TRIUMPH trials, demonstrating significant weight reduction in Phase 2 research.
Tirzepatide
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) studied for type 2 diabetes and chronic weight management, with extensive Phase 3 trial data.